Goldman Sachs Upgrades Chemours On Improving End Markets
Chemours Co.s (NYSE: CC ) near-term prospects are now brighter, driven by TiO2 cycle improvement and growth in the Fluoroproducts business due to a cyclical recovery and secular trends, according to Goldman Sachs. The Chemours Analyst: Robert Koort upgraded the rating for Chemours from Neutral to Buy, while raising the price target from $35 to $47. The Chemours Thesis: The TiO2 cycle is improving with the industrys efforts to stabilize pricing and pigment prices are now set to increase for the first Full story available on Benzinga.com
Goldman Sachs Upgrades Chemours On Improving End Markets
Chemours Co.s (NYSE: CC ) near-term prospects are now brighter, driven by TiO2 cycle improvement and growth in the Fluoroproducts business due to a cyclical recovery and secular trends, according to Goldman Sachs. The Chemours Analyst: Robert Koort upgraded the rating for Chemours from Neutral to Buy, while raising the price target from $35 to $47. The Chemours Thesis: The TiO2 cycle is improving with the industrys efforts to stabilize pricing and pigment prices are now set to increase for the first Full story available on Benzinga.com